Document is current
Any future updates will be listed below
-
Authors
Uomoto, Mari
Ota, Yukihide
Suzuki, Yukio
Yumori, Asuna
Narimatsu, Hiroto
Koizume, Shiro
Sato, Shinya
Nakamura, Yoshiyasu
Myoba, Shohei
Ohtake, Norihisa
Saji, Haruya
Miyagi, Etsuko
Miyagi, Yohei
-
Funding
Funding for this research was provided by:
Tosoh
Kanagawa Cancer Center (FY240009)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 19 August 2024
First Online: 27 August 2024
Declarations
:
: The experimental protocol of the present study was reviewed and approved by the Institutional Review Board of the Kanagawa Cancer Center Hospital (Ethics-2021-60). Written informed consent was obtained from the patients for publication of the study and accompanying images.
: Not applicable.
: SM and NO are employees of Tosoh Corporation, which provides E-test Tosoh II, an assay for measuring Tissue Factor Pathway Inhibitor 2 (TFPI2), a marker used to assist in the diagnosis of ovarian cancer. EM obtained a grant from the Tosoh Corporation outside the submitted work. YM obtained grants from the Tosoh Corporation, both for this work and outside of the submitted work. The other authors declare no conflicts of interest directly relevant to the content of this article.The analysis of serum TFPI2, CA125, CA19-9, and CEA levels was outsourced to the Tosoh Corporation by the Kanagawa Cancer Center.
: Springer Nature remains neutral regarding its jurisdictional claims in its published maps and institutional affiliations.
